These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24659794)

  • 1. Natalizumab in clinical practice: managing the risks, enjoying the benefits.
    Aktas O
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1181. PubMed ID: 24659794
    [No Abstract]   [Full Text] [Related]  

  • 2. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
    Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
    Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
    Magdolna S
    Ideggyogy Sz; 2014 May; 67(5-6):211-2. PubMed ID: 25087382
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
    Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired perforating dermatosis associated with natalizumab.
    Piqué-Duran E; Eguía P; García-Vázquez O
    J Am Acad Dermatol; 2013 Jun; 68(6):e185-7. PubMed ID: 23680214
    [No Abstract]   [Full Text] [Related]  

  • 6. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
    Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
    Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.
    van Kempen ZLE; van Rossum JA; Doesburg D; Claessen I; de Vries A; Ten Brinke A; van Oosten BW; Rispens T; Killestein J
    J Neurol; 2019 Jul; 266(7):1804-1805. PubMed ID: 31004214
    [No Abstract]   [Full Text] [Related]  

  • 9. Natalizumab therapy for multiple sclerosis.
    Chataway J; Miller DH
    Neurotherapeutics; 2013 Jan; 10(1):19-28. PubMed ID: 23307290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab for relapsing multiple sclerosis.
    Tenser RB
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract]   [Full Text] [Related]  

  • 15. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab and HSV meningitis.
    Shenoy ES; Mylonakis E; Hurtado RM; Venna N
    J Neurovirol; 2011 Jun; 17(3):288-90. PubMed ID: 21487835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
    Kappos L; Bates D; Edan G; Eraksoy M; Garcia-Merino A; Grigoriadis N; Hartung HP; Havrdová E; Hillert J; Hohlfeld R; Kremenchutzky M; Lyon-Caen O; Miller A; Pozzilli C; Ravnborg M; Saida T; Sindic C; Vass K; Clifford DB; Hauser S; Major EO; O'Connor PW; Weiner HL; Clanet M; Gold R; Hirsch HH; Radü EW; Sørensen PS; King J
    Lancet Neurol; 2011 Aug; 10(8):745-58. PubMed ID: 21777829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of natalizumab.
    Tanaka M
    Mult Scler; 2019 Oct; 25(12):1689-1690. PubMed ID: 30485149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.